| Quality assessment | No of patients | Effect | Quality | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Treatment versus no treatment | Control | Relative (95% CI) | Absolute | ||
| All-cause mortality - <140mmHg (follow-up mean 4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | very serious1 | no serious imprecision | none | - | - | RR 0.98 (0.9 to 1.07) | [4,897 events in 68, 16 people]5 |
⨁⨁◯◯ LOW | CRITICAL |
| All-cause mortality - 140–159mmHg (follow-up mean 4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | very serious1 | serious1 | none | - | - | RR 0.87 (0.75 to 1.01) | 7 fewer per 1000 (from 14 fewer to 1 more)3 |
⨁◯◯◯ VERY LOW | CRITICAL |
| All-cause mortality - ≥160mmHg (follow-up mean 4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | very serious1 | no serious imprecision | none | - | - | RR 0.93 (0.87 to 0.99) | 6 fewer per 1000 (from 1 fewer to 11 fewer)3 |
⨁⨁◯◯ LOW | CRITICAL |
| Stroke - <140 (follow-up mean 4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | very serious1 | serious1 | none | - | - | RR 0.85 (0.68 to 1.06) | 4 fewer per 1000 (from 10 fewer to 2 more)4 |
⨁◯◯◯ VERY LOW | CRITICAL |
| Stroke - 140–159 (follow-up mean 4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | very serious1 | serious1 | none | - | - | RR 0.86 (0.72 to 1.03) | 6 fewer per 1000 (from 12 fewer to 1 more)4 |
⨁◯◯◯ VERY LOW | CRITICAL |
| Stroke - ≥160 (follow-up mean 4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | very serious1 | no serious imprecision1 | none | - | - | RR 0.69 (0.6 to 0.79) | 19 fewer per 1000 (from 13 fewer to 25 fewer)4 |
⨁⨁◯◯ LOW | CRITICAL |
| Coronary heart disease - <140 mmHg (Copy; follow-up mean 4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | Very serious1 | no serious imprecision | none | - | - | RR 0.98 (0.88 to 1.09) | 1 fewer per 1000 (from 8 fewer to 6 more)4 |
⨁⨁◯◯ LOW | CRITICAL |
| Coronary heart disease - 140–159mmHg (Copy) | ||||||||||||
| 1 | no methodology chosen | no serious risk of bias | no serious inconsistency | Very serious1 | serious1 | none | - | - | RR 0.86 (0.76 to 0.97) | 5 fewer per 1000 (from 1 fewer to 8 fewer)4 |
⨁◯◯◯ VERY LOW | CRITICAL |
| Coronary heart disease - ≥160mmHg (Copy) | ||||||||||||
| 1 | no methodology chosen | no serious risk of bias | no serious inconsistency | Very serious1 | serious1 | none | - | - | RR 0.86 (0.78 to 0.95) | 8 fewer per 1000 (from 3 fewer to 12 fewer)4 |
⨁◯◯◯ VERY LOW | CRITICAL |
| Heart failure - <140mmHg (follow-up mean 4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | very serious1 | serious1 | none | - | - | RR 0.88 (0.78 to 0.99) | [2,261 events in 60,879 people]5 |
⨁◯◯◯ VERY LOW | IMPORTANT |
| Heart failure - 140–159mmHg (follow-up mean 4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | very serious1 | serious1 | none | - | - | RR 0.87 (0.73 to 1.04) | [1,113 events in 35,254 people]5 |
⨁◯◯◯ VERY LOW | IMPORTANT |
| Heart failure - ≥160mmHg (follow-up mean 4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | very serious1 | no serious imprecision | none | - | - | RR 0.53 (0.42 to 0.67) | [520 events in 23,395 people]5 |
⨁⨁◯◯ LOW | IMPORTANT |
Downgraded by 1 increment due to population or outcome indirectness or by 2 increments for both population and outcome indirectness.
Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.
Control group risk not reported; values extrapolated from Bulpitt 198838
Control group risk not reported; values extrapolated from Law 200990
Control group risk not reported; therefore, absolute risk could not be calculated: no data was available that values could be extrapolated from.
From: Evidence review for initiating treatment
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.